Patisiran

Patisiran is a transthyretin-directed small interfering RNA used to treat polyneuropathy of hereditary transthyretin-mediated amyloidosis. It is marketed as Onpattro which is formulated as patisiran within a liposome envelope for better delivery to the liver, where transthyretin is produced.

Mechanism
Curator reviewed
Primary indication
Patisirant is indicated for the treatment of hereditary transthyretin-mediated amyloidosis in adults.Curator reviewed · 1 structured indication
First approval
Canada, 2019 · United States, 2018 · European Union, 2021
Code names
ALN-18328 · ALN-TTR02
Brand names
  • Onpattro

Resolves to

Targets

What you can answer from here — as of July 17, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
11Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
4Marketed productsAcross 4 countries and 2 labellers
Sign in
1ATC codeIncluding every combination product, plus 15 drug categories
Sign in
7+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Patisiran, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account